Showing results (91-100 of 125) with videos related to
Sort By:
Pageof 13
The British Journal of Dermatology|November 12, 2009
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trialM Lebwohl, K Papp, C Han, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 5, 2011
Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinicJ Barker, E J Horn, M Lebwohl, et al.Journal of the American Academy of Dermatology|September 17, 1998
Cyclosporine consensus conference: with emphasis on the treatment of psoriasisM Lebwohl, C Ellis, A Gottlieb, et al.Journal of the American Academy of Dermatology|September 25, 2001
Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasisM Lebwohl, L Drake, A Menter, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 26, 2019
Itch: an under-recognized problem in psoriasisB Elewski, A F Alexis, M Lebwohl, et al.Journal of the American Academy of Dermatology|November 21, 1997
Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgarisA W Lucky, T A Henderson, W H Olson, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 12, 2019
Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasisM Lebwohl, R G Langley, Y Zhu, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 30, 2021
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trialR B Warren, M Lebwohl, H Sofen, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 15, 2020
Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trialsL Puig, T-F Tsai, T Bhutani, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|September 23, 2018
Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trialsA Blauvelt, K Reich, M Lebwohl, et al.Pageof 13